JP2007505044A - ポリアミン−金属キレーター接合体 - Google Patents

ポリアミン−金属キレーター接合体 Download PDF

Info

Publication number
JP2007505044A
JP2007505044A JP2006525542A JP2006525542A JP2007505044A JP 2007505044 A JP2007505044 A JP 2007505044A JP 2006525542 A JP2006525542 A JP 2006525542A JP 2006525542 A JP2006525542 A JP 2006525542A JP 2007505044 A JP2007505044 A JP 2007505044A
Authority
JP
Japan
Prior art keywords
group
moiety
substituted
compound
polyamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006525542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505044A5 (https=
Inventor
レイモンド ジェイ． ジュニア ベルジェロン，
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファウンデイション、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファウンデイション、インコーポレイテッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファウンデイション、インコーポレイテッド
Publication of JP2007505044A publication Critical patent/JP2007505044A/ja
Publication of JP2007505044A5 publication Critical patent/JP2007505044A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
JP2006525542A 2003-09-09 2004-09-09 ポリアミン−金属キレーター接合体 Pending JP2007505044A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50134103P 2003-09-09 2003-09-09
PCT/US2004/029318 WO2005023310A2 (en) 2003-09-09 2004-09-09 Polyamine-metal chelator conjugates

Publications (2)

Publication Number Publication Date
JP2007505044A true JP2007505044A (ja) 2007-03-08
JP2007505044A5 JP2007505044A5 (https=) 2007-10-25

Family

ID=34273034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525542A Pending JP2007505044A (ja) 2003-09-09 2004-09-09 ポリアミン−金属キレーター接合体

Country Status (8)

Country Link
US (1) US20080096974A2 (https=)
EP (1) EP1667727B1 (https=)
JP (1) JP2007505044A (https=)
AT (1) ATE400300T1 (https=)
AU (1) AU2004270261B2 (https=)
CA (1) CA2538159A1 (https=)
DE (1) DE602004014949D1 (https=)
WO (1) WO2005023310A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525495A (ja) * 2010-05-04 2013-06-20 シャイアー・リミテッド・ライアビリティ・カンパニー 金属キレート化剤としてのデスアザデスフェリチオシン類似体

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
TR201910900T4 (tr) 2005-04-04 2019-08-21 Univ Florida Desferritiyokin polieter analogları.
EP2065057A3 (en) * 2006-03-15 2009-08-12 Mallinckrodt Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
EP2101764A4 (en) * 2006-12-12 2010-02-17 Univ Florida ACTINIDE DECORATION AGENT WITH DESFERRITHIOCIN ANALOGON
WO2008115433A1 (en) 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues
EP2215052B1 (en) * 2007-11-01 2013-07-24 Rachel Codd Desferrioxamine conjugates, derivatives and analogues
JP5431361B2 (ja) 2008-01-09 2014-03-05 セルカ ゲーエムベーハー 改善された培養培地添加物及びそれを用いる方法
US7932326B2 (en) * 2008-04-16 2011-04-26 The University Of Kentucky Research Foundation Chelating compounds and immobilized tethered chelators
US9259670B2 (en) 2008-04-16 2016-02-16 The University Of Kentucky Research Foundation Flow-through filter to remove aluminum from medical solutions
MY163516A (en) 2008-07-14 2017-09-15 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
WO2011109521A1 (en) 2010-03-02 2011-09-09 University Of Kansas Polyamine-dihydroxybenzoic acid conjugate hydrogels as iron chelators
EP3620161A1 (en) 2011-12-16 2020-03-11 University of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
FR2984317B1 (fr) 2011-12-20 2015-02-27 Univ Rennes Composes chelateurs de metal presentant au moins une chaine polyaminee.
AU2014352780A1 (en) 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도
CA3022013C (en) 2016-04-29 2025-08-12 Ophirex, Inc. Secreted pla2 inhibitors for immediate treatment of hymenoptera envenomation
US12384856B2 (en) 2018-10-30 2025-08-12 The Research Foundation For The State University Of New York Compositions and methods for removal of negatively charged impurities using metal-cellulose fiber composite

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06505996A (ja) * 1991-08-23 1994-07-07 フアイザー・インコーポレイテツド 興奮性アミノ酸系神経伝達物質アンタゴニストとしての合成アリールポリアミン
JPH10506918A (ja) * 1994-12-21 1998-07-07 ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド デスフェリオキサミンｂおよびその同族体の合成方法
JP2000514089A (ja) * 1997-01-10 2000-10-24 ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド リゾフェリンの合成方法
JP2001512502A (ja) * 1997-01-21 2001-08-21 ナイコメッド・アマーシャム・ピーエルシー 標識した因子Ｘ▲ＩＩＩ▼ａ基体
JP2002523500A (ja) * 1998-08-31 2002-07-30 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド チアゾリン酸誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342945A (en) * 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US5091576A (en) * 1986-12-02 1992-02-25 University Of Florida Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US6184232B1 (en) * 1986-12-02 2001-02-06 University Of Florida Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment
US5554748A (en) * 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
US5886051A (en) * 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
US20040132789A1 (en) * 2002-08-22 2004-07-08 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06505996A (ja) * 1991-08-23 1994-07-07 フアイザー・インコーポレイテツド 興奮性アミノ酸系神経伝達物質アンタゴニストとしての合成アリールポリアミン
JPH10506918A (ja) * 1994-12-21 1998-07-07 ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド デスフェリオキサミンｂおよびその同族体の合成方法
JP2000514089A (ja) * 1997-01-10 2000-10-24 ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド リゾフェリンの合成方法
JP2001512502A (ja) * 1997-01-21 2001-08-21 ナイコメッド・アマーシャム・ピーエルシー 標識した因子Ｘ▲ＩＩＩ▼ａ基体
JP2002523500A (ja) * 1998-08-31 2002-07-30 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド チアゾリン酸誘導体

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN5006013263, ＫＯＮＴＯＧＨＩＯＲＧＨＥＳ Ｇ Ｊ, ＣＵＲＲＥＮＴ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ, 200408, Ｖ１１ Ｎ１６, Ｐ２１６１−２１８３ *
JPN6010042921, Ｂｉｏｃｏｎｊｕｇａｔｅ Ｃｈｅｍｉｓｔｒｙ, 2002, １３（２）, ｐ．３１７−３２６ *
JPN6010042922, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 2002, ４５（２３）, ｐ．５０９８−５１１１ *
JPN6010042923, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 2003, ４６（１３）, ｐ．２６７２−２６８２ *
JPN6010042924, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 2001, ４４（２２）, ｐ．３６５３−３６６４ *
JPN6010042925, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 1995, ３８（１３）, ｐ．２２７８−２２８５ *
JPN6010042926, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 2003, ４６（２５）, ｐ．５４７８−５４８３ *
JPN6010042927, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 2003, ４６（８）, ｐ．１４７０−１４７７ *
JPN6010042928, Ｂｉｏｃｈｅｍｉｃａｌ ａｎｄ Ｂｉｏｐｈｙｓｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ, 1984, １２１（３）, ｐ．８４８−８５４ *
JPN6010043046, Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｊｏｕｒｎａｌ ｏｆ Ａｐｐｌｉｅｄ Ｒａｄｉａｔｉｏｎ ａｎｄ Ｉｓｏｔｏｐｅｓ, 1982, ３３（５）, ｐ．３２７−３３２ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525495A (ja) * 2010-05-04 2013-06-20 シャイアー・リミテッド・ライアビリティ・カンパニー 金属キレート化剤としてのデスアザデスフェリチオシン類似体

Also Published As

Publication number Publication date
EP1667727B1 (en) 2008-07-09
DE602004014949D1 (de) 2008-08-21
EP1667727A2 (en) 2006-06-14
US20060211773A1 (en) 2006-09-21
US20080096974A2 (en) 2008-04-24
WO2005023310A3 (en) 2005-04-21
AU2004270261A1 (en) 2005-03-17
WO2005023310A2 (en) 2005-03-17
CA2538159A1 (en) 2005-03-17
ATE400300T1 (de) 2008-07-15
AU2004270261B2 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
JP2007505044A (ja) ポリアミン−金属キレーター接合体
JP2555391B2 (ja) 金属キレートー蛋白質複合体を形成するための主鎖多置換キレート
Hegetschweiler A rigid, cyclohexane-based polyamino-polyalcohol as a versatile building block for tailored chelating agents
US20200317730A1 (en) Targeted nitroxide agents
EP3541431B1 (en) Myeloperoxidase imaging agents
US9115094B2 (en) Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
US9687572B2 (en) PSMA-targeted dendrimers
EP2379493B1 (en) Process for the preparation of asymmetrical bis(thiosemicarbazones)
US20230044430A1 (en) Composition and method for modifying polypeptides
US20190388569A1 (en) Multifunctional chelators, complexes, and compositions thereof, and methods of using same
US10894096B2 (en) 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents
JP7646637B2 (ja) 画像化及び治療用組成物
Santos et al. Bifunctional 3-hydroxy-4-pyridinone derivatives as potential pharmaceuticals: Synthesis, complexation with Fe (III), Al (III) and Ga (III) and in vivo evaluation with 67Ga
CA2739445A1 (en) Site specific n-terminal modifications of proteins and conjugate formation
HK1245276B (zh) 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法
CN1426391A (zh) 作为细胞毒剂的多胺类似物
US20150209452A1 (en) Metal-binding bifunctional compounds as diagnostic agents for alzheimer's disease
WO2013092556A1 (fr) Composés chélateurs de métal présentant au moins une chaîne polyaminée
CZ271198A3 (cs) Biokonjugáty manganu nebo komplexy železa makrocyklických ligandů obsahujících dusík, působící jako katalyzátory pro dismutaci superoxidu
EP3011976A1 (en) 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
US10968224B2 (en) 2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents
Gateau et al. Rational Design of Copper and Iron Chelators to Treat Wilson's Disease and Hemochromatosis
US20240226343A1 (en) Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof
Steiner et al. Fluorescent Deferoxamine Complexes of Cu (II) and Zr (IV): Insights in the Development of Dual Imaging Probes
Burke The Synthesis and Biological Activity of Iron Binding Motifs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100728

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100730

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110328